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Abstract 
Influenza virus infection in pigs is a major farming problem, causing considerable economic loss and posing a 
zoonotic threat. In addition the pig is an excellent model for understanding immunity to influenza viruses as this is a 
natural host pathogen system. Experimentally, influenza virus is delivered to pigs intra‑nasally, by intra‑tracheal instil‑
lation or by aerosol, but there is little data comparing the outcome of different methods. We evaluated the shedding 
pattern, cytokine responses in nasal swabs and immune responses following delivery of low or high dose swine influ‑
enza pdmH1N1 virus to the respiratory tract of pigs intra‑nasally or by aerosol and compared them to those induced 
in naturally infected contact pigs. Our data shows that natural infection by contact induces remarkably high innate 
and adaptive immune response, although the animals were exposed to a very low virus dose. In contacts, the kinetics 
of virus shedding were slow and prolonged and more similar to the low dose directly infected animals. In contrast the 
cytokine profile in nasal swabs, antibody and cellular immune responses of contacts more closely resemble immune 
responses in high dose directly inoculated animals. Consideration of these differences is important for studies of 
disease pathogenesis and assessment of vaccine protective efficacy.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Influenza A virus (IAV) is an important zoonotic patho-
gen that can cause substantial mortality and rapidly dis-
seminate through economically important avian (ducks 
and chickens) and mammalian (human, swine and other) 
populations [1–3]. H1N1 and H3N2 subtypes of IAV are 
endemic in pigs and humans, in addition to H1N2 in 
pigs. Because human origin viruses or viruses containing 
human origin gene segments frequently adapt to transmit 
efficiently in pigs [4, 5] the pig is a source of new viruses 
capable of initiating epidemics or pandemics in humans 
of mixed swine, human and avian origin [6].
As both pigs and humans are readily infected with IAVs 
of similar subtype, the pig is a robust and appropriate 
model for investigating both swine and human disease. 
Like humans, pigs are outbred, and physiologically, ana-
tomically and immunologically similar to humans. The 
porcine lung also resembles the human in terms of its 
tracheobronchial tree structure, lung physiology, mor-
phology and distribution of receptors bound by influenza 
A viruses [3, 7]. Thus studies of the infection dynamics of 
pandemic (pdm) A/(H1N1)09 origin viruses in pigs may 
also throw light on factors affecting transmission and 
infection in humans.
However very few studies have evaluated the impor-
tance of dose and route of delivery of swine influenza virus 
(SwIV) in experimental challenge studies. Experimentally 
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SwIV is typically delivered to the airways of pigs by intra-
nasal inoculation with a syringe [8, 9], intra-nasally with a 
mucosal atomisation device (MAD) [10–12] or by intra-
tracheal instillation [13–17]. The intra-tracheal route is 
reported to result in infections that cause more severe 
morbidity [13, 14, 18, 19] that are a reflection of the 
greater virus replication in the lung, while severe mor-
bidity is rare with intra-nasal challenge. Intra-tracheal 
delivery is widely used because of its reproducibility and 
consistency, however the virus is delivered to the lower 
respiratory tract (LRT) and bypasses the upper respira-
tory tract (URT), which is the natural route of infection. 
In contrast the aerosol route approximates more closely 
the natural route of transmission as it targets the LRT but 
via the URT [20, 21] and has been described as showing 
more severe clinical signs [22]. However, very few chal-
lenges have been performed using aerosol delivery. In 
order to determine the most relevant model for assess-
ment of IAV pathogenesis, transmission, vaccine efficacy 
or therapeutic intervention, we examined whether experi-
mental delivery of SwIV to the URT or LRT intra-nasally 
or by aerosol respectively, best represents natural infec-
tion. To do this we evaluated the virus shedding patterns 
and immune responses of pigs after intra-nasal (IN) and 
aerosol (AERO) challenge with different doses and com-
pared these to animals that had become infected by con-
tact transmission, the “natural” route.
Materials and methods
Animals and influenza virus challenge
Animal experiments were approved by the Pirbright 
Institute and APHA ethics committees, according to the 
UK Animal (Scientific Procedures) Act 1986. Eight to 
nine week old landrace cross, female pigs were obtained 
from a commercial high health status herd. All pigs used 
were derived from the same cohort, sourced at the same 
time and acclimatized for a period of 7  days. Pigs were 
screened for absence of IAV infection by matrix (M) gene 
real time RT-PCR [23] and antibody-free status was con-
firmed using haemagglutination inhibition (HAI) with 4 
SwIV antigens. Pigs were inoculated with the strain A/
Sw/Eng/1353/09, provided by Dr Sharon Brookes, APHA 
(DEFRA SwIV surveillance programme SW3401). The 
inoculum stock was propagated in the allantoic cavities 
of 9–11-day-old embryonated specific-pathogen-free 
hens’ eggs. For all serological and immunological assays, 
the virus was propagated in Madin-Darby canine kidney 
(MDCK) cells.
Groups of four pigs were challenged with either 1 × 104 
egg infectious doses EID50 (low dose) or groups of three 
pigs were challenged with 1 × 107 EID50 (high) of virus. 
Virus delivery was performed either by aerosol (AERO) 
in 1  mL following sedation or by the intra-nasal route 
(IN) using a mucosal atomization device, MAD300 
(Wolfe Tory Medical) with 2  mL of virus administered 
to each nostril, of non-sedated animals. For aerosol chal-
lenge an InnoSpire Deluxe Philips Respironics nebulizer 
was fixed to a small-sized anaesthetic mask held over the 
animal’s nose and mouth. The animals were sedated with 
5  mg/kg ketamine hydrochloride and 1  mg/kg Stresnil: 
azaperone administered intramuscularly.
Two days after the high dose challenge, three naïve 
pigs were co-housed with the 3 AERO challenged pigs 
and three further naïve pigs with the 3 IN infected pigs 
for 48 h, after which they were moved to separate clean 
rooms (experimental design in Figure 1A).
In total 8 pigs were challenged with low dose: 4 by 
AERO (A, B, C, D) and 4 by IN (F, G, H, I); 6 were chal-
lenged with high dose: 3 by AERO (E, J, K) and 3 by IN (L, 
M, N); and 6 were infected were co-housed with infected 
pigs: 3 co-housed with AERO (R, S, T) challenged pigs 
and 3 with IN (O, P, Q) challenged.
Animals were monitored by observing demeanour, 
appetite and respiratory signs such as coughing and 
sneezing. Body temperatures were monitored using an 
Identichip Biothermal microchip. Animals were eutha-
nized at 14 days post-infection (dpi) or 16 days post-con-
tact (dpc) with an overdose of intravenous pentobarbital 
sodium.
Aerosol droplet size characterization
The average droplet size produced by each of the MAD 
(IN) and nebuliser (AERO) devices was characterised 
using laser diffraction as previously described [24]. 
Briefly, the devices were loaded with PBS to their speci-
fied maximum fill volumes and connected to the inlet of 
the droplet sizer. The device under test was turned on 
and run until the entire dose was delivered. Testing was 
carried out in triplicate.
Tissue sample processing
Four nasal swabs (two per nostril) were taken daily from 
day 0 until the day of euthanasia at the end of the study. 
The four nasal swabs from each sampling were placed 
together into 2  mL of Leibovitz medium (Gibco), con-
taining 1% foetal bovine serum (FBS) and 1% penicillin/
streptomycin. The tubes containing the swabs were agi-
tated, swabs were removed, and the supernatant was ali-
quoted and stored at −80 °C for subsequent analysis.
Clotted and heparin anticoagulated blood samples 
were taken before the challenge and at 4, 7, 11, 14 dpi 
for the animals infected with a low dose of virus and at 3, 
7, 10 and 14 dpi for animals infected with a high dose of 
virus, blood was taken from contact animals at 2, 5, 9, 12 
and 16 dpc. For PBMC isolation heparinised blood was 
diluted 1:1 in PBS before density gradient centrifugation 
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at 1200×g for 30  min over Histopaque® 1.083  g/mL 
(Sigma-Aldrich). PBMC were harvested from the inter-
face, washed in PBS and contaminating red blood cells 
lysed using ammonium chloride lysis buffer, washed 
again and cryopreserved in FBS (Gibco) with 10% (v/v) 
DMSO (Sigma).
Broncho-alveolar lavage (BAL) was performed post 
mortem, by washing the lung with 250  mL of PBS and 
A Low dose - 1 x 104 EID50
dpi  0              2                 4
d14
High dose  - 1 x 10 7 EID 50
d14
d16
3 IN contacts
3 AERO contacts
4 IN
4 AERO
3 IN
3 AERO
dpi  0              2                 4
dpc 0              2                 4
Contacts
B
Figure 1 Experimental design and virus shedding of AERO, intranasal and contact challenge. A Pigs were challenged with 1 × 104 EID50 
(low) or 1 × 107 EID50 (high) of A/Sw/Eng/1353/09 virus by aerosol (AERO) or intra‑nasally (IN). After 2 days three naïve pigs were co housed with 
each of the AERO high or IN high animals and after further 2 days moved to separate rooms. Horizontal lines indicate the time scale of the experi‑
ment and the vertical bars show challenge, time of contact and sacrifice. B Viral titers in nasal swab suspensions for indicated groups. The viral titres 
are represented by markers. Each line represents an individual within the indicated group.
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harvesting 100 mL of the fluid. BAL cells were isolated 
by centrifuging the lavage fluid at 800 ×  g for 15  min, 
supernatant was aliquoted and frozen for antibody 
detection, the cell pellet was washed in PBS, filtered 
twice using a 70  µM cell strainer and cryopreserved. 
Tracheo-bronchial lymph nodes (TBLN) were dissected 
at post mortem, cut into 1–5  mm pieces, before fur-
ther dissociation into a single cell suspension using the 
GentleMACS Octo (Miltenyi), and C tubes (Miltenyi) 
with 3 mL of complete medium RPMI (Gibco) supple-
mented with 10% FBS and penicillin/streptomycin. The 
cell suspension was filtered using a 70 μM cell strainer 
and washed in PBS. All cells were cryopreserved in 
FBS with 10% DMSO at a minimum concentration of 
1 × 107 cells/mL.
Virus titration in nasal swabs
Viral titres in nasal swab suspensions were determined 
by plaque assay on MDCK cells. Duplicate samples were 
tenfold serially diluted and 100 μL medium added to con-
fluent MDCK cells in 12 well tissue culture plates. After 
1 h, the plates were washed and overlayed with 2 mL 1:3 
2% (w/v) agarose:medium. Plates were incubated at 37 °C 
for 48 h and plaques visualized by staining the monolayer 
with 0.1% (v/v) crystal violet.
Viral RNA levels in nasal swabs were also quanti-
fied by RRT-qPCR by amplification of the M gene. RNA 
was extracted from 140  μL swab suspension using the 
QIAamp viral RNA mini kit and Biorobot extraction 
(Qiagen) according to the manufacturer’s protocol. The 
assay conditions used were as previously described [25]. 
Viral RNA present per mL of nasal swab suspension was 
correlated to relative equivalent units (REU) of infectious 
virus per millilitre using a ten-fold dilution series of RNA 
purified from infective allantoic fluid and using an inter-
run standard containing RNA equivalent to a known 
EID50 titre of A/sw/Eng/1353/09.
Pathological examination of lungs
To assess the lung pathology groups of 4 pigs were also 
challenged with 1.5 ×  105  pfu/pig of intermediate dose 
of MDCK-grown A/Sw/Eng/1353/09 (equivalent to 
6 × 106 EID50) by the IN or AERO routes. The MDCK- 
and egg-grown viruses used in this study were sequenced 
and confirmed to be identical. The animals were 
humanely killed 4 dpc with an overdose of pentobarbi-
tal sodium anaesthetic. At post mortem the lungs were 
removed and digital photographs taken of the dorsal and 
ventral aspects. Macroscopic pathology scoring was per-
formed blind using Nikon-NIS Br software to determine 
the proportion of the total surface area of the lung (dor-
sal and ventral aspects) affected by typical influenza-like 
gross lesions.
HAI assay
Influenza virus specific antibody (Ab) titres in serum 
and BAL fluid were determined by HAI using standard 
protocols [11]. Briefly, H1N1 HAI antibody titres were 
determined using 0.5% chicken red blood cells and A/
Sw/Eng/1353/09 live antigen at a concentration of 4 HA 
units/mL.
IFN‑γ ELISPOT
Frequencies of IFN-γ secreting cells in PBMC, BAL cells 
and TBLN cells were determined by ELISPOT using 
previously cryopreserved cells. MultiScreen™-HA ELIS-
POT plates (Merck Millipore), were coated with 0.5 μg/
mL of anti-pig IFN-γ, clone P2G10 (BD Pharmingen) in 
carbonate buffer and incubated at 4  °C overnight. The 
plates were washed 5 times in PBS and blocked using 4% 
(w/v) milk powder in PBS for 2 h. After 5 washes in PBS, 
5 ×  105 cells were seeded in triplicate wells and stimu-
lated with either live MDCK-grown A/Sw/Eng/1353/09 
(MOI = 5), medium control or 10 μg/mL Con A (Sigma-
Aldrich). Plates were incubated for 40 h at 37 °C in a 5% 
CO2 incubator, followed by five washes with PBS, 0.05% 
Tween20 and addition of 0.25  μg/mL anti-pig bioti-
nylated IFN-γ detection Ab, clone P2C11 (BD Pharmin-
gen). Plates were incubated for 2 h at room temperature, 
washed 5 times and streptavidin alkaline phosphatase 
(Invitrogen) was added for a further 1 h at room temper-
ature. Spots were visualised using alkaline phosphatase 
substrate kit (BioRad) and the reaction was stopped using 
tap water. Immunospots were counted using the AID 
ELISPOT reader (AID Autoimmun Diagnostika). Results 
were expressed as number of IFN-γ-producing cell per 
106 cells after subtraction of the average number of IFN-
γ+ cells in medium control wells.
Flow cytometry
Cryopreserved PBMC and cells from TBLN and BAL 
were thawed and stimulated for 12  h at 37  °C with live 
MDCK-grown virus strain A/Sw/Eng/1353/09 (MOI 6 
for BAL and PBMC, MOI 0.6 for TBLN) or MDCK mock 
supernatant as control. GolgiPlug (BD Biosciences) was 
added according to the manufacturer’s instructions for 
a further 5 h before intracellular cytokine staining. Cells 
were stained for surface markers with CD3ε-PeCy5 PPT3 
(AbCam), biotinylated CD4 clone MIL17 (in-house), with 
secondary streptavidin-APC (Southern Biotec), CD8α-
FITC MIL12 (AbD Serotec) and Near-Infrared Fixable 
Live/Dead stain (Invitrogen). Cells were permeabilized 
using Cytofix Cytoperm (BD Biosciences) as per the 
manufacturer’s instructions before intracellular staining 
(ICS) with IFN-γ PE P2G10 (AbD Serotec). Samples were 
fixed in 1% paraformaldehyde before analysis using an 
LSR Fortessa instrument (BD Biosciences).
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Data was analysed using FlowJo v10 (Treestar), fluores-
cence of control samples stained with one primary anti-
body omitted were used to set gates. Samples were batch 
gated on lymphocytes based on SSCA/FSCA, followed by 
single cells on SSCH/SSCA. Live CD3 positive cells were 
analysed for expression of CD4 and CD8α. Boolean gat-
ing was used to determine the levels of IFN-γ in CD8α 
high, CD4CD8α double positive and CD4 T cell subsets.
Detection of cytokines
The presence of IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12, IFN-
α, IFN-γ and TNFα in nasal swabs was determined using 
ProcartaPlex Cytokine&Chemokine panel 1 (nineplex, 
Affymetrix, eBioscience) according to the manufactur-
er’s instructions. Results were quantified on a Luminex® 
200™ and cytokine and chemokine concentrations in 
the samples were determined using a standard curve for 
each cytokine (with lower limits of detection respectively 
0.092, 0.072, 0.428, 1.420, 1.250, 1.463, 0.00, 1.245 and 
2.272 pg/mL). All results were obtained in duplicate and 
represented as the mean.
Distribution of Evans Blue in lungs and pathological 
analysis after IN or AERO administration
Evans Blue (Sigma-Aldrich), 5% solution in PBS was 
administered by aerosol using either nebuliser or intra-
nasal MAD device as described for the influenza A virus 
challenge above. After 20 min pigs were euthanized with 
an overdose of intravenous administered pentobarbi-
tal sodium. A detailed post mortem investigation of the 
upper and lower respiratory tract was conducted.
Statistical analysis
To analyse influenza viral kinetics we estimated the initial 
viral load, V0, which is the necessary viral load at inocula-
tion to induce the subsequent viral kinetic, the ascending 
slope, s1, the time of the peak, Tmax and the descending 
slope, s2, using the segmented linear regression pack-
age called “segmented 0.5–0.0” in R 3.1 [26]. Parameter 
fitting was performed by maximum-likelihood method, 
using the log-scaled viral loads. The data was truncated to 
keep virus-positive samples. In addition we included two 
samples where the viral titre is below the limit of quan-
tification, one before and one after the shedding period. 
We tested the association of the individual parameters 
between the dose groups (low, high, contact) or route 
group (AERO, IN, contact) using pairwise permuta-
tional t test from the package “RVAideMemoire 0.9–55” 
in R 3.1.1. We used 1000 permutations and p value was 
adjusted for multiple testing with the Benjamini and 
Hochberg method [27]. In the case of pigs which did not 
have a virus-positive sample on any occasion after the 
challenge, we performed the analysis after their exclu-
sion. From the individual estimated parameters, we also 
predicted for each pig the height of viral titre peak com-
puted as: Vmax = V0 + s1*Tmax and characterized the viral 
shedding period as the time during which viral titre is >1 
log10 (log10 PFU/mL). The start of shedding period was 
computed as Tstart =  (1−V0)/s1, the end of the shedding 
period as Tend  =  (1−(Vmax−s2))/s2 and the duration of 
shedding period as Tend−Tstart.
IL-6, IL-8 and IL-1β were used for statistical analy-
sis as greater than half the samples assayed showed lev-
els above the limit of quantification. The remaining 
cytokines: IFNα, IFNγ, IL-10, IL12p40, IL-4 and TNFα 
had greater than 78% of their data below the lower limit 
of quantification. Data for IL-6, IL-8 and IL-1β were 
transformed prior to analysis to correct for non-normal-
ity. IL-8 was log10 transformed and IL-6 and IL-1β were 
square root transformed. Data that were below the lower 
limit of quantification (LLOQ) were set to half LLOQ. 
Only data up to (and including) day 6 were included in 
order to standardise the analysis. Baseline samples were 
excluded as the time of sampling was not equivalent for 
all pigs. Principal components analysis (PCA) was run on 
the cytokine data matrix (20 pigs, 3 variables and 6 time 
points) using PC-ORD software version 6.03 (MJM soft-
ware Design, Gleneden Beach, OR). PCA was used with a 
Euclidian distance measure after relativizing by standard 
deviates of the columns. The final set of components was 
determined using stopping procedures [28]. A second 
matrix was created including virus titre, day and chal-
lenge groups. Data within the second matrix was overlaid 
onto the final PCA to look for associations with cytokine 
levels. The strength of the correlation along principal 
component (PC) 1–2 for continuous variables was meas-
ured using Kendall’s τ nonparametric correlation coef-
ficient. Significance of the τ correlation was determined 
using proc freq in SAS version 9.1.3 (SAS Institute Inc., 
Cary, NC). Significance of the categorical variables were 
assessed using Multi-response Permutation Procedures 
(MRPP) analysis, a nonparametric procedure for testing 
the hypothesis of no difference between two and more 
groups [29].
To describe the immune responses of each treatment 
group, the number of input variables was reduced using 
PCA (R statistical software version 3.3.0) to investigate 
underlaying principal components. Data from the HAI 
assay, IFN-γ ELISPOT and flow cytometry were included 
in the analysis, virus and cytokine data were excluded. 
Principal components 1–5 (PC1–PC5) were submitted 
for analysis using individual general linear models, fol-
lowed by post hoc tests using Tukey adjusted-least sig-
nificant means.
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Results
Kinetics of virus shedding following aerosol, intranasal 
and contact infection with influenza virus
To determine the role of dose and route of infection 
on virus shedding and immune responses, pigs were 
infected with A/Sw/Eng/1353/09 influenza virus. They 
were challenged either with a low (1  ×  104  EID50) or 
high (1  ×  107  EID50) dose of virus either by aerosol 
(AERO) using a nebuliser, which generates small drop-
lets believed to target the lower respiratory tract (LRT) 
or intra-nasally (IN) using a MAD, which produces large 
droplets believed to be mostly deposited in the upper res-
piratory tract (URT). Using laser diffraction, the average 
droplet size produced by the MAD device was measured 
as 105.7 ± 14.1 μm. The fine particle fraction (FPF) less 
than 5 μm, i.e. the aerosol fraction considered capable of 
deposition in the LRT, was 0%. The average droplet size 
produced by the nebuliser was 3.8 ± 0.1 μm with a FPF of 
63.4%. Groups of naïve pigs were co-housed with each of 
the high dose directly infected groups at 2 dpi and moved 
to separate rooms after a further 48  h (Figure  1A). The 
clinical signs observed were mild and none of the pigs 
developed moderate or severe disease. Gross pathol-
ogy was minimal in all animals at the time of sacrifice at 
14 dpi or 16 dpc.
Virus was detected in the nasal swabs of all 4 ani-
mals in the AERO low group, with the start of shedding 
between 2 and 4 dpi (Figure 1B). However only 2 of the 
4 animals in the IN low dose group shed any detectable 
virus. In contrast, all animals in the IN high dose group 
started shedding virus 1 dpi and virus was detected until 
5 dpi, while the animals in the AERO high dose started 
shedding virus at 2 dpi and virus could only be detected 
for 3 or 4 days. Furthermore the animals in the IN high 
group not only started shedding virus earlier, but also 
shed more virus compared to the AERO high group (Fig-
ure 1B). Because all IN high animals shed more virus, all 
of the three IN contacts were infected and shed virus by 3 
dpc. In contrast only 2 of the 3 AERO contacts shed virus 
at 2 and 4 dpc, while the third animal started shedding on 
7 dpc, most likely a result of contact infection from one 
of its companions.
To analyse the kinetics of virus shedding we estimated 
the initial viral load, V0, the ascending slope, s1, the time 
of the peak, Tmax, the descending slope, s2, and the start 
and duration of viral shedding (Table 1). We also used the 
estimated parameters to predict the height of peak virus 
shedding (Additional file 1). The IN and AERO contacts 
were combined in one group for analysis as they repre-
sent natural infection (analysis with separate IN or AERO 
contacts gave similar results, not shown). The effects of 
either route or dose of challenge on viral kinetics were 
compared between the groups and with the contacts. 
Analysis by route showed that V0 was significantly differ-
ent between the groups, with the IN high group showing 
the highest viral load, followed by the AERO high and 
contacts (Table 1). The viral load measured at 1 dpi in the 
high IN group should be considered with caution as it is 
not possible to differentiate virus shed from input virus. 
The end of the viral shedding period was also significantly 
different between contacts and the other groups as the 
contacts shed until 9.3 dpc (Tend ranging between 5.9 dpi 
for AERO high and 7.3 dpi for AERO low, Table 1). Anal-
ysis by dose on the other hand, indicates that the contacts 
are similar to the low dose pigs in all parameters except 
for V0 and the end of shedding while they showed multi-
ple significant differences from high dose animals.
We also measured virus shedding by RRT-qPCR, which 
gave similar results although the sensitivity was higher, 
resulting in molecular detection of low equivalent titres 
of virus in comparison to plaque assay for infectious viri-
ons. Overall there was a good agreement between viral 
titre measured by plaque assay and by PCR (Additional 
file  2), although molecular detection enabled monitor-
ing of virus shedding kinetics over a longer duration. By 
RRT-qPCR, only Tmax was significantly different between 
groups (p  =  0.01) with an earlier peak for pigs inocu-
lated with high dose (2.3  dpi for IN high) than for pigs 
inoculated with low dose or by contact (5.1  dpc). This 
is consistent with other studies demonstrating that viral 
titre measured by plaque assay represent infectious virus, 
whereas PCR measure total infectious and non-infectious 
viral RNA [30].
Taken together these data indicate that a lower dose 
is required for AERO infection compared to the dose 
required to establish infection by the IN route, based on 
the animal groups inoculated with a low dose of virus 
and that AERO infected animals transmit infection less 
efficiently, based on the animal groups inoculated with 
a high dose of virus. In contrast IN infection, requires 
a higher dose of virus to infect, but these animals start 
shedding one day earlier and shed more virus over the 
duration of virus egress. IN infected animals transmit-
ted virus more efficiently, as all of their contacts were 
infected. The pattern of viral kinetics of contacts differed 
from all of the other directly infected groups in terms 
of the initial viral load and end of the shedding period. 
Nevertheless, the results for infection kinetics of contact 
animals, suggest that low dose challenge is more compa-
rable to natural infection, in terms of viral kinetics and 
that AERO low delivery is more reproducible that IN low.
Cytokines in nasal swabs
Cytokines and chemokines are produced early after 
infection as part of the innate immune response to path-
ogens and therefore we determined whether the dose and 
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route of infection affects the innate immune response, 
assessed by analysing cytokine levels in nasal swabs. We 
measured IFN-α, IFN-γ, TNF-α, IL-1β, IL-4, IL-6, IL-8, 
IL-10, IL-12, between 0 to 6 dpi or dpc. However only 
IL-6, IL-8 and IL-1β were used for PCA as they were the 
only cytokines with greater than half of their measure-
ments above the limit of quantification Figure  2A. We 
also measured cytokines in serum and BAL fluid but did 
not find any correlation between the responses in nasal 
swabs, serum and BAL fluid (Table 2).
The results of the principal component analysis (PCA) 
are shown using 2D ordination graphs of the distance 
between sample units which approximates increas-
ing time (days) and viral titre (Figure  2B). PC1, which 
explains 78.9% of the variation in the data, is associated 
with high levels of IL-6 (p < 0.001) and IL-1β (p < 0.001). 
IL-8 was associated with both PC1 (p  <  0.001) and 
PC2 (p  <  0.001). PC1 is associated with high virus titre 
(p  <  0.001) and increasing time (day) (p  <  0.001). The 
contacts were significantly different from the low dose 
directly challenged pigs by both routes of inoculation 
(AERO low p  =  0.02 and IN low p  =  0.02). However 
there were no differences between the contacts and the 
AERO high (p =  0.1) or IN high (p =  0.1) groups. For 
low doses there was no significant difference between the 
routes of inoculation (p = 0.8) but the AERO high and IN 
high groups differed significantly (p = 0.006).
These data showed that the cytokine profiles of the 
naturally infected contacts were more similar to the high 
dose than low dose directly challenged animals.
Antibody and cellular immune responses
We next determined whether the dose and route of infec-
tion affect the adaptive immune response. HAI titres in 
serum and BAL fluid are shown in Table  3. The high-
est HAI titers were detected in the serum of the AERO 
high (1:256 ± 0) and both contact groups (AERO contact 
1:170.7 ± 73.9 and IN contact 1:128.0 ± 110.9). Similarly, 
the highest HAI titer in the BAL fluid was detected in the 
AERO high animals (64 ± 0) (Table 3).
We analysed the influenza A virus (1353/09 homolo-
gous stimulation) specific T cell responses in PBMC, 
BAL and TBLN by IFN-γ ELISPOT on 14 dpi and 16dpc 
(Figure  3A). The AERO high and low groups showed 
the highest virus specific PBMC responses (mean 
87 ±  59 SFC per 106 cells for AERO high, 72 ±  49 for 
AERO low, compared to 33 ± 39.4 and 30 ± 3.5 for IN 
high and IN low groups and 40 ± 33.6 and 36.7 ± 14.2 
for the AERO and IN contacts). The AERO and IN con-
tacts had the highest numbers of IFN-γ secreting cells 
in BAL (respectively 159.2  ±  120.3 and 140.9  ±  26.8 
SFC per 106 cells); whereas much lower responses were 
seen in the remaining animals (Figure 3A). In TBLN the 
AERO high challenge induced the strongest IFN-γ ELIS-
POT response followed by the IN contacts and AERO 
low, while responses in both IN groups were very low 
(Figure 3A).
We performed intracellular staining for IFN-γ follow-
ing in vitro stimulation with A/Sw/Eng/1353/09. In BAL 
a similar trend to the IFN-γ ELISPOT was observed 
with the contacts and AERO high and low directly chal-
lenged showing higher IFN-γ response by CD4, CD8 
and CD4CD8, compared to IN challenged animals 
(Figure 3B).
PCA was performed with PC1 explaining 29.6% of the 
variation in the immune reponses of the different treat-
ment groups and was significantly associated with group 
(p = 0.001) (Figure 3C). There were no significant differ-
ences between the contacts and both AERO and IN high 
dose groups (AERO high p =  0.8, IN high p =  0.5). In 
contrast contacts were significantly different from both 
low dose groups (AERO low p = 0.02, IN low p = 0.01). 
There were also no significance differences between 
the high dose groups (p = 0.2) or between the low dose 
groups (p =  1). None of the remaining PCAs were sig-
nificantly associated with treatment group. Interestingly, 
when the PC loadings were considered it was appar-
ent that intracellular cytokine production by PBMCs 
was positively loaded on PCA1, while IFN-γ production 
by cells in the ELISPOT assay was negatively loaded, 
indicating that the two techniques measured different 
immunological parameters (Additional file 3). A possible 
explanation could be that other cells such as NK cells are 
detected in the ELISPOT, while ICS detected only CD4 
or CD8 T cells. Antibody levels, as measured by HAI in 
BAL and serum, correlated with IFN-γ secretion by cells 
in the BAL and with IFN-γ production by CD4+CD8+ T 
cells in the TBLN.
In summary, in contrast to the viral kinetics, the anti-
body and cellular immune responses of the naturally 
infected contacts were similar to the high dose directly 
infected animals and significantly different to the low 
dose animals. Although there was a trend for higher 
immune responses in the AERO high compared to the IN 
high animals this did not reach statistical significance.
Distribution of Evans blue dye in the respiratory tract 
and lung pathology after AERO and IN delivery
To establish the distribution of material after AERO and 
IN delivery, we examined the respiratory tract after deliv-
ery of Evans Blue dye by MAD or aerosol [31]. IN admin-
istration using a MAD device resulted in delivery of dye 
to the URT and the digestive tract. Dye was found within 
the nasal cavity mucosa, and a very small amount within 
the larynx and the upper trachea (Figures 4A and B). In 
addition, considerable quantities of dye could be found in 
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Figure 2 Cytokines in nasal swabs. A Concentrations of IL‑1β, IL‑6 and IL‑8 for each infected group. Each line within the graphs represents an 
individual within the indicated group. B Principal component (PC) analysis for IL‑6, IL‑8 and IL‑1β. Scatterplot with vectors showing the direction and 
strength of the correlation of IL‑6, IL‑8, IL‑1β, virus titre and time along PC1 and PC2.
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the oral cavity, oropharynx, oesophagus (Figure 4A) and 
the stomach. This is consistent with the expected depo-
sition profile of droplets of ~105  μm in diameter, while 
some excess dye also runs down the back of the throat 
and is swallowed. In these circumstances, any deposition 
in the lung would be expected to be as a result of aspira-
tion of Evans Blue from the nasopharynx and/or larynx.
After aerosol delivery dye was found within the nasal 
cavity mucosa, the larynx, trachea and the entire respira-
tory tree from the large bronchi towards the bronchioles 
and including the lung parenchyma (alveoli). This is in 
accord with expectations, as droplets of ~3.8 μm in diam-
eter would efficiently transit through the nasal cavity and 
into and throughout the LRT. Some deposition would 
be expected in the nasal cavity given the turbulent air-
flow through the turbinates (Figures 4C and D). A small 
amount of dye was found in the oesophagus. This is likely 
explained by Evans Blue again running down the back of 
the throat.
Because of the distinct patterns of dye distribution, we 
compared the lung pathology 4 days after IN and AERO 
administration of A/Sw/Eng/1353/09 influenza virus. 
Typical influenza-induced gross pathology was found in 
lungs from both groups although in the AERO the lesions 
were affecting different areas of the lung including the 
more distal parts of the lobes, while the IN, gross lesions 
were fewer in numbers and localised closer to the big 
bronchi (Figures 4F–H). The pulmonary lesions consisted 
of multifocal areas of consolidation, dark in colour and 
consistent with necrotising bronchiolitis and atelectasis 
[32].
Taken together these data indicate that IN delivery dis-
tributes the dye in the URT and the digestive tract, while 
AERO results mainly in a wider distribution within the 
LRT, i.e. respiratory tree, including the lung parenchyma 
within the proximal and distal parts of all lung lobes. 
Nevertheless even with IN administration the lung does 
become infected albeit with a more localised distribution 
of lesions.
Discussion
Although aerosol is one of the natural routes of SwIV 
transmission, very few studies have been performed using 
aerosol challenge and to date there had been no head-
to head comparisons of IN, AERO and natural contact 
infection. As the pig provides a key component in study-
ing pathogenesis of IAV and assessment of anti-viral 
Table 2 Serum and BAL fluid A/Sw/Eng/1353/09 specific 
HAI titres
HA titres were determined in serum and BAL fluid at day of sacrifice (14 or 
16 dpc) using 4 HAI units of A/Sw/Eng/1353/09 virus. Results shown are the 
mean of all individuals in each of the groups ± standard deviation. Serum from 
pigs immunized with commercial A(H1N1)pdm09 vaccine Pandemrix (GSK) and 
challenged with A/England/195/09 (pdmH1N1) virus as previously described 
[11] was used as a positive control and gave a titer of 2048.
Group Animal Serum BALF
Pre‑chal‑
lenge
14 dpi/16 dpc 14 dpi/16 dpc
AERO low A 16 32 16
B 4 64 32
C 8 64 32
D 8 32 8
IN low E 16 64 16
F 16 16 16
G 8 128 16
H 16 32 16
AERO high I 16 256 64
J 8 256 64
K 16 256 64
IN high L 8 32 16
M 8 64 16
N 16 128 16
IN contact O 16 256 32
P 16 64 16
Q 16 64 16
AERO con‑
tact
R 8 128 16
S 16 128 32
T 8 256 32
Table 3 Cytokine concentrations in serum and BALF of AERO and IN infected pigs
Cytokine concentrations (pg/mL) in the serum and BAL fluid at the day of sacrifice of AERO and IN high groups were determined using a commercial Luminex assay.
Group Animal IL‑10 IL‑12p40 IL‑8
Serum BALF Serum BALF Serum BALF
AERO high I 0.9 ND 216.5 2.4 288.7 260
J 11.5 ND 184.6 6.1 239.4 141.9
K 20.3 ND 394.9 3.9 101.9 79.8
IN high L ND ND 490.4 7.5 152.4 523.5
M ND ND 98.6 4.2 173.4 125.5
N ND ND 472.8 2.2 218.8 162.6
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therapies, an understanding of the impact of the route of 
delivery is essential to allow comparison of data gener-
ated using different challenge models. Our results indicate 
that influenza A swine pH1N1 viral kinetics and immune 
response in naturally infected contact animals differ from 
those of animals experimentally infected by different 
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Figure 3 Cytokine responses in PBMC, BAL and TBLN. Pigs were inoculated with 1 × 104 EID50 (low, circles) or 1 × 107 EID50 (high, squares) of 
A/Sw/Eng/1353/09 virus by AERO (open symbols) or IN (solid symbols) or by contact with the high dose AERO infected pigs (open diamonds) or by 
contact with the high dose IN infected pigs (solid diamonds) as indicated on the figure. A Numbers of IFNγ secreting cells in PBMC, BAL and TBLN 
at 14 dpi or 16 dpc were determined by ELISPOT. B The percentage of IFNγ producing cells in BAL was determined by intracellular cytokine staining 
and flow cytometry at 14 dpi or 16 dpc. Cytokine expression is presented as a percentage of the total number of cells in CD4+, CD4+CD8+ and 
CD8+ cells. Each data point represents an individual within the indicated group and the horizontal lines indicates the mean. C Box and whisker 
plots of the scores of PC1 (29.59% explained variance) for immune response in each treatment group. Each boxplot represents the distribution of 
estimates for pigs in the indicated groups.
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doses and routes. In contacts, the kinetics of virus shed-
ding were slow, prolonged and more similar to the low 
dose directly infected animals. In contrast the cytokine 
profile in nasal swabs, antibody and cellular immune 
responses of contacts more closely resemble immune 
responses in high dose directly inoculated animals.
Figure 4 Distribution of Evans Blue and lesions in lungs. Groups of six pigs were administered Evans Blue either IN or by AERO. IN delivery of 
Evans Blue resulted in heavy staining within the alimentary canal (oesophagus, white arrow) and a very small amount in the upper trachea (black 
arrow) (A), no deposit in the lower trachea nor the rest of the respiratory tract or the lung parenchyma (B). AERO administration resulted in wide‑
spread distribution within the entire respiratory tract (C) including the lung parenchyma as observed through the pleura (D) or after sectioning the 
lung (E). The percentage of lung surface with influenza‑like lesions varied in each animal with a higher score in AERO than IN (F). The distribution of 
lesions showed a small number of lung lobes with lesions in IN (G) compared to the majority of lung lobes in AREO (H).
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We also show that successful infection of pigs can be 
achieved with a much lower dose of virus by AERO than 
IN administration. Aerosol administration of influenza A 
virus to human volunteers demonstrates that fewer than 
ten virions can initiate infection and similar results have 
been obtained in the ferret model [21, 33, 34]. Addition-
ally, influenza A virus in small droplets has been shown to 
be 100 times more infectious than influenza virus in large 
droplets [35]. Although IN challenge required a higher 
dose for successful infection, once infected, animals pro-
duced more virus and were better able to transmit infec-
tion, since all of the IN high contacts became infected. In 
contrast the animals given a high dose of virus by AERO 
did not transmit efficiently, suggesting that virus replicat-
ing in the LRT is more efficiently contained and less likely 
to be emitted than that in the URT. This is in agreement 
with transmission studies in ferrets, showing a significant 
correlation between virus titer in nasal washes and the 
likelihood of virus transmission, indicating that replica-
tion in the URT is the source of virus for both direct con-
tact and airborne transmission [33].
Our results also demonstrate that natural infection is 
highly efficient in generating strong immune responses. 
Both innate and adaptive immune responses in the con-
tacts are comparable to the responses in AERO and IN 
high dose directly challenged animals, yet viral kinetics 
indicate that the contacts received a low infectious dose. 
This paradox suggests that natural infection with a low 
dose is highly efficient in inducing an immune response 
and the response elicited is similar to that following 
experimental delivery of a high dose to either to the 
URT or LRT. We speculate that natural infection targets 
both the URT and LRT and therefore reaches the great-
est number of antigen presenting cells and many lymph 
nodes, enabling the host to mount a strong and efficient 
protective immune response. On the other hand from the 
perspective of the virus, reaching the greatest number of 
receptor bearing cells gives it the best chance to infect 
and transmit.
In humans and ferrets aerosols of <5 μm are capable of 
reaching deep into the LRT and reaching alveolar tissues. 
Using Evans Blue dye we have shown that MAD delivery 
of ~105  μm droplets results in deposition in the URT 
and the digestive tract, while nebuliser-generated aerosol 
results in a wider distribution within the respiratory tree, 
including the lung parenchyma within the proximal and 
distal parts of all lung lobes. At first sight it is surprising 
that IN and AERO delivery which showed such different 
patterns of dye delivery, both generated strong immune 
responses. However this maybe because dye distribution 
does not represent what happens with infectious SwIV. 
As Figure  4F shows, pigs administered virus IN or by 
AERO both showed lung pathology. IN delivery by MAD 
is a widely used method for experimental pig challenge 
because of its technical expediency and many studies 
show that it is reproducible. We hypothesize that with 
MAD delivery of a high dose of virus sufficient mate-
rial reaches the LRT to evoke an LRT immune response, 
although we and others have shown that the most effi-
cient way to reach the LRT and induce an immune 
response is by aerosol [12, 36–38]. Further work using a 
larger group of animals will be required to confirm the 
differences in these readouts between IN, AERO and 
contact routes of infection.
In summary our data show that the inoculation method 
used for assessing immunity to SwIV and vaccine efficacy 
is critical in determining the outcome. High dose IN chal-
lenge results in a much higher virus titer in nasal swabs at 
day 1 compared to contact infected animals and it may 
be difficult to show protective efficacy, especially of T 
cell based vaccines, which do not prevent virus entry into 
cells. While contact infection may be optimal, it requires 
more animals and is consequently expensive. Low dose 
aerosol challenge may provide the next best alternative 
to natural infection. Our comparison of IN, AERO and 
contact infected animals shows that the route of infection 
and the dose of infectious virus may affect the outcome 
in terms of infectivity, viral shedding, immune response 
and pathology. Consideration of these differences is 
important for studies of disease pathogenesis and assess-
ment of vaccine protective efficacy.
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